{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:35:09Z","timestamp":1791822909921,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03270-z","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:41:10Z","timestamp":1750171270000},"page":"3945-3959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Real-World Outcomes between Patients with BRCA1\/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Mehmet A.","family":"Bilen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabree","family":"Burbage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khilfeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lowentritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"3270_CR1","unstructured":"American Cancer Society. Key statistics for prostate cancer. https:\/\/www.cancer.org\/cancer\/prostate-cancer\/about\/key-statistics.html. Accessed 28 November 2024"},{"key":"3270_CR2","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results. Cancer stat facts: prostate cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed 28 November 2024"},{"issue":"4","key":"3270_CR3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/JU.0000000000001570","volume":"205","author":"N Shore","year":"2021","unstructured":"Shore N, Oliver L, Shui I, et al. Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations. J Urol. 2021;205(4):977\u201386.","journal-title":"J Urol"},{"issue":"25","key":"3270_CR4","doi-asserted-by":"publisher","first-page":"40222","DOI":"10.18632\/oncotarget.16712","volume":"8","author":"M Cui","year":"2017","unstructured":"Cui M, Gao XS, Gu X, et al. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer. Oncotarget. 2017;8(25):40222\u201332.","journal-title":"Oncotarget"},{"issue":"8","key":"3270_CR5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/pros.23795","volume":"79","author":"M Oh","year":"2019","unstructured":"Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis. Prostate. 2019;79(8):880\u201395.","journal-title":"Prostate"},{"key":"3270_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae183","author":"MA Bilen","year":"2025","unstructured":"Bilen MA, Khilfeh I, Rossi C, et al. Treatment patterns for patients with BRCA1\/2-positive metastatic castration-resistant prostate cancer. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyae183.","journal-title":"Oncologist"},{"key":"3270_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/CEOR.S468680","volume":"16","author":"MA Bilen","year":"2024","unstructured":"Bilen MA, Khilfeh I, Rossi C, et al. Homologous recombination repair testing patterns and outcomes in mCRPC by alteration status and race. Clinicoecon Outcomes Res. 2024;16:657\u201374.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"9","key":"3270_CR8","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/biomedicines9091247","volume":"9","author":"I Henriquez","year":"2021","unstructured":"Henriquez I, Roach M 3rd, Morgan TM, et al. Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC). Biomedicines. 2021;9(9):1247.","journal-title":"Biomedicines"},{"issue":"9","key":"3270_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","volume":"34","author":"KN Chi","year":"2023","unstructured":"Chi KN, Sandhu S, Smith MR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34(9):772\u201382.","journal-title":"Ann Oncol"},{"issue":"1","key":"3270_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Azad AA, Matsubara N, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024;30(1):257\u201364.","journal-title":"Nat Med"},{"issue":"8","key":"3270_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719\u201332.","journal-title":"N Engl J Med"},{"key":"3270_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102726","volume":"126","author":"RR McKay","year":"2024","unstructured":"McKay RR, Morgans AK, Shore ND, et al. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: applying clinical study findings to clinical practice in the United States. Cancer Treat Rev. 2024;126: 102726.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"3270_CR13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): Final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(10):1094\u2013108.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3270_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo J, de Bono JS, Fizazi K, et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial. J Clin Oncol. 2024;42(5):571\u201383.","journal-title":"J Clin Oncol"},{"key":"3270_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS176","author":"DE Rathkopf","year":"2021","unstructured":"Rathkopf DE, Chi KN, Olmos D, et al. AMPLITUDE: a study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_suppl.TPS176.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3270_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2217\/fon-2023-0526","volume":"20","author":"N Agarwal","year":"2024","unstructured":"Agarwal N, Saad F, Azad AA, et al. TALAPRO-3 clinical trial protocol: Phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 2024;20(9):493\u2013505.","journal-title":"Future Oncol"},{"issue":"9","key":"3270_CR17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/oncolo\/oyae120","volume":"29","author":"MC Markowski","year":"2024","unstructured":"Markowski MC, Sternberg CN, Wang H, et al. TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations. Oncologist. 2024;29(9):794\u2013800.","journal-title":"Oncologist"},{"key":"3270_CR18","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. 2020. arXiv:2001.09765."},{"key":"3270_CR19","doi-asserted-by":"crossref","unstructured":"Ma X, Long L, Moon S, et al. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2023:2020.03.16.20037143.","DOI":"10.1101\/2020.03.16.20037143"},{"issue":"6","key":"3270_CR20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/1475-6773.13669","volume":"56","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Gossai A, Monroe S, et al. Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States. Health Serv Res. 2021;56(6):1281\u20137.","journal-title":"Health Serv Res"},{"issue":"5","key":"3270_CR21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1377\/hlthaff.2017.1579","volume":"37","author":"V Agarwala","year":"2018","unstructured":"Agarwala V, Khozin S, Singal G, et al. Real-world evidence in support of precision medicine: clinico-genomic cancer data as a case study. Health Aff (Millwood). 2018;37(5):765\u201372.","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"3270_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12885-020-07714-3","volume":"21","author":"LM Hess","year":"2021","unstructured":"Hess LM, Han Y, Zhu YE, et al. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. BMC Cancer. 2021;21(1):28.","journal-title":"BMC Cancer"},{"issue":"9","key":"3270_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237802","volume":"15","author":"R Woodhouse","year":"2020","unstructured":"Woodhouse R, Li M, Hughes J, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE. 2020;15(9): e0237802.","journal-title":"PLoS ONE"},{"issue":"6","key":"3270_CR24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228\u201334.","journal-title":"Commun Stat Simul Comput"},{"issue":"5","key":"3270_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos D, Lorente D, Alameda D, et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024;35(5):458\u201372.","journal-title":"Ann Oncol"},{"issue":"1","key":"3270_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/bju.16462","volume":"135","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Hoeh B, Koll F, et al. Impact of homologous recombination repair\/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer. BJU Int. 2025;135(1):117\u201324.","journal-title":"BJU Int"},{"issue":"6","key":"3270_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clgc.2022.06.016","volume":"20","author":"AM Lee","year":"2022","unstructured":"Lee AM, Saidian A, Shaya J, et al. The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer. Clin Genitourin Cancer. 2022;20(6):515\u201323.","journal-title":"Clin Genitourin Cancer"},{"issue":"22","key":"3270_CR28","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.2217\/fon-2021-0153","volume":"17","author":"N Shore","year":"2021","unstructured":"Shore N, Ionescu-Ittu R, Yang L, et al. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. Future Oncol. 2021;17(22):2907\u201321.","journal-title":"Future Oncol"},{"issue":"8","key":"3270_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2217\/fon-2021-1113","volume":"18","author":"A Leith","year":"2022","unstructured":"Leith A, Ribbands A, Kim J, et al. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan. Future Oncol. 2022;18(8):937\u201351.","journal-title":"Future Oncol"},{"issue":"4","key":"3270_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.eururo.2020.12.039","volume":"79","author":"AS Merseburger","year":"2021","unstructured":"Merseburger AS, Waldron N, Ribal MJ, et al. Genomic testing in patients with metastatic castration-resistant prostate cancer: a pragmatic guide for clinicians. Eur Urol. 2021;79(4):519\u201329.","journal-title":"Eur Urol"},{"key":"3270_CR31","doi-asserted-by":"publisher","first-page":"4986365","DOI":"10.1155\/2020\/4986365","volume":"2020","author":"C Messina","year":"2020","unstructured":"Messina C, Cattrini C, Soldato D, et al. BRCA mutations in prostate cancer: Prognostic and predictive implications. J Oncol. 2020;2020:4986365.","journal-title":"J Oncol"},{"issue":"5","key":"3270_CR32","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.euo.2024.02.005","volume":"7","author":"J Xie","year":"2024","unstructured":"Xie J, Guo H, Dong B, et al. Olaparib combined with abiraterone versus olaparib monotherapy for patients with metastatic castration-resistant prostate cancer progressing after abiraterone and harboring DNA damage repair deficiency: a multicenter real-world study. Eur Urol Oncol. 2024;7(5):1088\u201396.","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"3270_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.euo.2023.08.004","volume":"7","author":"M Schostak","year":"2024","unstructured":"Schostak M, Bradbury A, Briganti A, et al. Practical guidance on establishing a molecular testing pathway for alterations in homologous recombination repair genes in clinical practice for patients with metastatic prostate cancer. Eur Urol Oncol. 2024;7(3):344\u201354.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"3270_CR34","first-page":"360","volume":"72","author":"VN Giri","year":"2022","unstructured":"Giri VN, Morgan TM, Morris DS, et al. Genetic testing in prostate cancer management: considerations informing primary care. CA Cancer J Clin. 2022;72(4):360\u201371.","journal-title":"CA Cancer J Clin"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03270-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03270-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03270-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:00:24Z","timestamp":1757188824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03270-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3270"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03270-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mehmet A. Bilen is a professor at Emory University School of Medicine and has acted as a paid consultant for and\/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi; and has received grants to his institution from Xencor, Bayer, Bristol-Myers Squibb, Genentech\/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer for work performed as outside of the current study. Sabree Burbage and Ibrahim Khilfeh are employees and stockholders of Johnson & Johnson. Carmine Rossi, Lilian Diaz, Yuxi Wang, and Dominic Pilon are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Johnson & Johnson, which funded the development and conduct of this study and manuscript. Gordon Brown is an employee of New Jersey Urology and has received consulting fees from Johnson & Johnson. Neal Shore is an employee of the START Carolinas\/Carolina Urologic Research Center and has received consulting fees from Johnson & Johnson, Bayer, Dendreon, Tolmar, Ferring, Medivation\/Astellas, Amgen, Pfizer, AstraZeneca, Astellas Pharma, AbbVie, Merck, Bristol Myers Squibb\/Sanofi, Exact Imaging, FerGene, InVitae, MDxHealth, Myriad Genetics, Propella Therapeutics, Genzyme, Sanofi, CG Oncology, Genesis Cancer Care, Urogen pharma, Speciality Networks, PeerView, Clarity Pharmaceuticals, Lantheus Medical Imaging, Lilly, Photocure, Telix Pharmaceuticals, AIkido Pharma, Arquer Diagnostics, Asieris Pharmaceuticals, Minomic, Novartis, PlatformQ Health, Promaxo, Protara Therapeutics, Fize Medical, Accord Research, Antev, Aura Biosciences, Bioprotect, and Sumitomo Pharma Oncology. Neal Shore has received research funding from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb\/Pfizer, Boston Scientific, Clovis Oncology, Dendreon, Exact Imaging, Ferring, Foundation Medicine, InVitae, Janssen, MDxHealth, Merck, Myovant Sciences, Myriad Genetics, Nymox, Pfizer, Sanofi, Sesen Bio, Tolmar, CG Oncology, DisperSol, FORMA Therapeutics, Guardant Health, Jiangsu Yahong Meditech, Novartis, Pacific Edge, POINT Biopharma, Propella Therapeutics, SeaGen, MT Group, Theralase, Veru, Zenflow, Advantagene, Aragon Pharmaceuticals, Endocyte, Exelixis, FKD Therapies, Genentech, Istari Oncology, Medivation, OncoCellMDx, ORIC Pharmaceuticals, Palette Life Sciences, Plexxikon, RhoVac, Steba Biotech, Urogen pharma, Urotronic, US Biotest, and Vaxiion for work performed outside of the current study. Benjamin Lowentritt is an employee of Chesapeake Urology and has received consulting fees from Johnson & Johnson, Dendreon, Astellas Pharma, Bayer, AstraZeneca\/MedImmune, Merck, Tolmar, AbbVie, Pfizer, and Myovant Sciences. Daniel W. Lin is an employee of the University of Washington and Fred Hutchinson Cancer Center and has received consulting fees from AstraZeneca, Astellas, Janssen, and Lantheus and research funding to the institution from MDxHealth, MagForce USA, and Veracyte.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was considered exempt research under 45 CFR \u00a7 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR \u00a7 164.514.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}